Skip to content
value.today

Genesis Therapeutics, Inc.

🇺🇸 Burlingame, California, USABiotechnologyFounded 2019
Total raised
$297 M
3 rounds on record
Latest round
$224 M
Aug 2023
First round on record
Nov 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genesis Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$224 MNo. 3$50 to $250 million

Genesis Therapeutics, Inc.: Raise no. 3, Aug 2023

Investors in this round

50 investors had bought by the notice of Aug 25, 2023: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Genesis Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$224 M of $224 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Sklaroff · Executive Officer
  • Evan Feinberg · Executive Officer, Director
  • Peptiboon Prasit · Executive Officer, Director
  • William Mccarthy · Executive Officer
  • Kris Jenner · Director
  • Leonard Bell · Director
  • Vijay Pande · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evan Feinberg, President and ceo. Source: SEC Form D, newest notice filed Aug 25, 2023. Read the notice at the SEC.

equitySEC
Jun 2022$24 MNo. 2$10 to $50 million

Genesis Therapeutics, Inc.: Raise no. 2, Jun 2022

Investors in this round

33 investors had bought by the notice of Dec 23, 2022: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Genesis Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Sklaroff · Executive Officer
  • Evan Feinberg · Executive Officer, Director
  • Stephen Dann · Executive Officer
  • William Mccarthy · Executive Officer
  • Kris Jenner · Director
  • Leonard Bell · Director
  • Peptiboon Prasit · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evan Feinberg, President and ceo. Source: SEC Form D, newest notice filed Dec 23, 2022. Read the notice at the SEC.

optionsSEC
Nov 2020$50 MNo. 1$10 to $50 million

Genesis Therapeutics, Inc.: Raise no. 1, Nov 2020

Investors in this round

24 investors had bought by the notice of Dec 9, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Genesis Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Sklaroff · Executive Officer
  • Evan Feinberg · Executive Officer, Director
  • Nicholas Stock · Executive Officer
  • Kris Jenner · Director
  • Leonard Bell · Director
  • Peptiboon Prasit · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evan Feinberg, President and ceo. Source: SEC Form D, newest notice filed Dec 9, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genesis Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2023

That is all the official record says: Genesis Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Genesis Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
BlackRock Health Sciences Term TrustFund or asset manager$10 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT
BlackRock Health Sciences Opportunities PortfolioFund or asset manager$6 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
BlackRock Health Sciences TrustFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genesis Therapeutics, Inc.
NameRoleNamed in
Benjamin SklaroffExecutive officerAug 2023
Evan FeinbergExecutive officerAug 2023
Peptiboon PrasitExecutive officerAug 2023
William MccarthyExecutive officerAug 2023
Stephen DannExecutive officerDec 2022
Nicholas StockExecutive officerDec 2020
Evan FeinbergDirectorAug 2023
Kris JennerDirectorAug 2023
Leonard BellDirectorAug 2023
Peptiboon PrasitDirectorAug 2023
Vijay PandeDirectorAug 2023